| 词条 | Ralimetinib |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- | image = Ralimetinib.png | alt = | caption = Ralimetinib structural formula | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = PO | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 862505-00-8 | class = | ATCvet = | ATC_prefix = none | ATC_suffix = | PubChem = 11539025 | DrugBank = | ChemSpiderID = 9713805 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D10658 | C= 24| H= 29| As= | Au= | Br= | Cl= | Co= | F= 1| Gd= | I= | Mn= | N= 6| Na= | O= | P= | Pt= | S= | Se= | Sr= | Tc= | Zn= | charge= | molecular_weight = | smiles = C12C(=CC=C(N=1)C1=C(N=C(N1)C(C)(C)C)C1C=CC(=CC=1)F)N=C(N2CC(C)(C)C)N | StdInChI = 1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30) | StdInChIKey = XPPBBJCBDOEXDN-UHFFFAOYSA-N }} Ralimetinib (LY2228820) is a small molecule experiemental cancer drug in development by Eli Lilly. It is a p38 mitogen-activated protein kinase inhibitor. A phase II trial for treatment of ovarian cancer is expected to be complete in February 2017.[1] References1. ^https://clinicaltrials.gov/ct2/show/NCT01663857 5 : Experimental cancer drugs|Fluoroarenes|Imidazoles|Protein kinase inhibitors|Tert-butyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。